Hematology

Study findings suggest that enhanced cleaning and disinfecting policies are effective at reducing the spread of COVID-19.

A more sensitive test capable of detecting heart function issues early in cancer treatment may be beneficial in preventing heart failure.

The research will have implications for clinicians when prescribing blood-thinning medications after Fontan surgery, a complex congenital heart disease operation redirecting blood flow from the lower body to the lungs.

Presentation provides an overview of recent FDA approvals for therapies utilized in patients with various cancer types.

Health care providers should monitor blood pressure starting in early adolescence, especially for individuals at high cardiovascular risk, such as Black populations.

Data show that 1 in 5 men and women worldwide develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease, according to the study.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic the next steps for his CAEL-101 findings, a treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic his recent CAEL-101 findings, and how it can help shape treatment for patients living with amyloid light chain amyloidosis.

The BTD designations for asciminib were based on the phase 3, multicenter, open-label, randomized ASCEMBL trial and a phase I trial that included patients with Ph+ CML, some of them harboring the T315I mutation.

Of 192 study participants who received Breyanzi, 73% achieved a response, including 54% who had minimal or no detectable lymphoma remaining following treatment and 19% who achieved a partial response.

The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about what CAEL-101 is, how it works, and how it is used to treat patients with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.

Since its introduction to the US market in 2003, questions have risen as to the safety, long-term consequences, and risk of cardiovascular detriments that e-cigarettes pose to users.

Rather than having an intrinsically lower risk of severe COVID-19, the patients in the study may have adhered more strictly to social distancing guidelines compared to the general population.

Patients with AML that has gone into remission following initial chemotherapy were found to remain in remission longer and have improved OS if they took a pill form of azacitidine as a maintenance treatment.

The study authors found marked improvements in rates of hazardous prescribing over the 12-month study period and the success of the intervention was sustained at the end.

Stroke is not among the covered diagnoses for cardiac rehab, despite many similar cardiovascular risk factors, according to the study.

Numerous therapeutic options are available for acute myeloid leukemia, but more research is needed to determine how best to use them.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

The blood test measures levels of mitochondrial DNA, which is a unique type of DNA molecule that normally resides inside the energy factories of cells.

New treatment approach is designed to treat retracted blood clots, which form over extended periods of time and are especially dense.

Crizotinib is the first biomarker-driven therapy for relapsed or refractory anaplastic large cell lymphoma in children and young adults.

The FDA has granted an orphan drug designation to the BCMA-targeted trispecific T-cell activating recombinant protein construct as treatment for patients with multiple myeloma.

The current study provides characterization of a lipid-rich necrotic core, a dangerous type of coronary plaque made up of dead cells and cell debris that is prone to rupture, which can lead to a heart attack or stroke.